Injectable Skin Cancer Treatments (Intralesional Therapy)

Trials of a novel injectable treatment for basal cell carcinoma are due to begin in Australia in 2015. ASN-002 is based on a genetically modified form of human adenovirus type 5. When injected into the tumor, the adenovirus infection causes an immune response against the cancer and also shuts off the blood supply to the cancer. A second drug, PV-10 contains an injectable formulation of rose bengal disodium, a water-soluble xanthene dye.19 This method of drug administration allows for delivery of an increased concentration of the agent and reduces systemic exposure, thereby increasing local efficacy and limiting toxicity.20


Continue Reading